Temme L - Search Results

1

Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.

Asquith CRM, Temme L, East MP, Laitinen T, Pickett J, Kwarcinski FE, Sinha P, Wells CI, Johnson GL, Zutshi R, Drewry DH. Asquith CRM, et al. Among authors: temme l. ChemMedChem. 2022 Jun 20;17(12):e202200161. doi: 10.1002/cmdc.202200161. Epub 2022 May 9. ChemMedChem. 2022. PMID: 35403825 Free PMC article.

2

Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes.

Eduful BJ, O'Byrne SN, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte JR, Hossain MA, Wells CI, Zuercher WJ, Catta-Preta CMC, Zonzini Ramos P, Santiago AS, Couñago RM, Langendorf CG, Nay K, Oakhill JS, Pulliam TL, Lin C, Awad D, Willson TM, Frigo DE, Scott JW, Drewry DH. Eduful BJ, et al. Among authors: temme l. J Med Chem. 2021 Aug 12;64(15):10849-10877. doi: 10.1021/acs.jmedchem.0c02274. Epub 2021 Jul 15. J Med Chem. 2021. PMID: 34264658 Free PMC article.

3

eEF2K: an atypical kinase target for cancer.

Temme L, Asquith CRM. Temme L, et al. Nat Rev Drug Discov. 2021 Aug;20(8):577. doi: 10.1038/d41573-021-00124-5. Nat Rev Drug Discov. 2021. PMID: 34257429 No abstract available.

4

PKN3: a target in cancer metastasis.

Temme L, Laitinen T, Asquith CRM. Temme L, et al. Nat Rev Drug Discov. 2022 Oct;21(10):704. doi: 10.1038/d41573-022-00154-7. Nat Rev Drug Discov. 2022. PMID: 36104477 No abstract available.

5

STK19: a new target for NRAS-driven cancer.

Asquith CRM, Temme L. Asquith CRM, et al. Among authors: temme l. Nat Rev Drug Discov. 2020 Sep;19(9):579. doi: 10.1038/d41573-020-00116-x. Nat Rev Drug Discov. 2020. PMID: 32587355 No abstract available.

6

Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.

Dey S, Temme L, Schreiber JA, Schepmann D, Frehland B, Lehmkuhl K, Strutz-Seebohm N, Seebohm G, Wünsch B. Dey S, et al. Among authors: temme l. Eur J Med Chem. 2017 Sep 29;138:552-564. doi: 10.1016/j.ejmech.2017.06.068. Epub 2017 Jul 1. Eur J Med Chem. 2017. PMID: 28704758

7

Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation.

Temme L, Frehland B, Schepmann D, Robaa D, Sippl W, Wünsch B. Temme L, et al. Eur J Med Chem. 2018 Jan 20;144:672-681. doi: 10.1016/j.ejmech.2017.12.054. Epub 2017 Dec 18. Eur J Med Chem. 2018. PMID: 29289890

8

Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds.

Temme L, Bechthold E, Schreiber JA, Gawaskar S, Schepmann D, Robaa D, Sippl W, Seebohm G, Wünsch B. Temme L, et al. Eur J Med Chem. 2020 Mar 15;190:112138. doi: 10.1016/j.ejmech.2020.112138. Epub 2020 Feb 10. Eur J Med Chem. 2020. PMID: 32070917

9

Impact of hydroxy moieties at the benzo[7]annulene ring system of GluN2B ligands: Design, synthesis and biological evaluation.

Temme L, Börgel F, Schepmann D, Robaa D, Sippl W, Daniliuc C, Wünsch B. Temme L, et al. Bioorg Med Chem. 2019 Dec 1;27(23):115146. doi: 10.1016/j.bmc.2019.115146. Epub 2019 Oct 8. Bioorg Med Chem. 2019. PMID: 31648876

10

Comparative Pharmacological Study of Common NMDA Receptor Open Channel Blockers Regarding Their Affinity and Functional Activity toward GluN2A and GluN2B NMDA Receptors.

Temme L, Schepmann D, Schreiber JA, Frehland B, Wünsch B. Temme L, et al. ChemMedChem. 2018 Mar 6;13(5):446-452. doi: 10.1002/cmdc.201700810. Epub 2018 Feb 16. ChemMedChem. 2018. PMID: 29377520

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page